Simrit Parmar News Today

NEW YORK, Nov. 4, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor...

/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of...

NEW YORK, Oct. 24, 2023 (GLOBE NEWSWIRE) --

HONG KONG, April 30, 2022 /PRNewswire/ -- Global Cord Blood Corporation Announces Entry into Cell Therapy Market by Acquiring Cellenkos and Its Products Rights

/PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO, "GCBC" or the "Company"), Chinas leading provider of cord blood collection, laboratory testing,...

/PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO, "GCBC" or the "Company"), Chinas leading provider of cord blood collection, laboratory testing,...

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Author of the article: Nick Lees  •  Edmonton Journal Publishing date: May 02, 2021  •  2 hours ago  •  3 minute read  •  UPLOADED BY: Nick Lees ::: EMAIL: nleesyeg@gmail.com ::: PHONE: 7804823603 ::: CREDIT: Supplied ::: CAPTION: Global TV anchor and producer Gord Steinke and his wife Deb have enjoyed motorbike trips in the Rockies during the COVID-19 pandemic and are pictured here taking a break at the north end of Jaspers Medicine Lake. When the going is safe, the coupl...

Incyte and Cellenkos Enter into Global Development Collaboration Agreement for CK0804 WILMINGTON, Del.--(Business Wire)--Incyte (Nasdaq:INCY) and Cellenkos, Inc., a privately held, clinical stage biotech company, today announced a development collaboration to investigate the combination of ruxolitinib (Jakafi ®) and CK0804, Cellenkos’ cryopreserved CXCR4 enriched, allogeneic, umbilical cord blood-derived T-regulatory cells, in patients with myelofibrosis (MF). In addition, Incyte has an ex...

®) and CK0804, cord blood-derived T-regulatory cells, in patients with myelofibrosis -   WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte (Nasdaq:INCY) and Cellenkos, Inc., a privately held, clinical stage biotech company, today announced a development collaboration to investigate the combination of ruxolitinib (Jakafi ®) and CK0804, Cellenkos’ cryopreserved CXCR4 enriched, allogeneic, umbilical cord blood-derived T-regulatory cells, in patients with myelofibrosis (MF). In addition, Incyte has...